Top

Published in:

01-06-2015 | Epidemiology

Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis

Authors: Fangfang Liu, Mu Yang, Zhenhua Li, Xiaojing Guo, Yang Lin, Ronggang Lang, Beibei Shen, Gordon Pringle, Xinmin Zhang, Li Fu

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Abstract

Invasive micropapillary carcinoma of breast (IMpC) is a special type of breast cancer with frequent lymph node metastasis (LNM) and poor prognosis, while pure mucinous carcinoma of breast (PMC) is generally associated with infrequent LNM and better prognosis. A similar micropapillary epithelial growth pattern has been described in PMC that was named as invasive micropapillary mucinous carcinoma (IMpMC), but its prognostic significance is as yet not known. A retrospective review of 531 cases of PMC in 43,685 cases of breast cancer diagnosed over a 10-year period was conducted to assess the frequency of IMpMC and its prognostic implications. IMpMC was identified in 134 (25.2 %) of the 531 PMC cases. Compared to conventional PMC (cPMC), IMpMC was found more frequently in younger patients and in tumors with increased frequency of LNM and lymphovascular invasion, and higher HER2 expression. In stage-matched Kaplan–Meier analysis, patients with stage II–III IMpMC suffered a decreased overall survival and recurrence-free survival (RFS) than matched cPMC patients. Multivariate analysis confirmed the presence of IMpMC morphology was an independent unfavorable predictor for LNM and RFS of PMC. However, decreased LNM, lower nuclear grade, higher expression of ER and PR, less expression of HER2, and better prognosis were identified in IMpMC when compared with IMpC (n = 281). This is the first study to show the prognostic significance of IMpMC in a large cohort. IMpMC pursues a more aggressive clinical course than cPMC and should be managed differently; therefore, recognition of IMpMC and its accurate diagnosis are clinically important.

Tavassoli FDP (2003) World Health Organization classification of tumours. IARC Press, Lyon

Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G (2004) Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol 121(6):857–866CrossRefPubMed

Walsh MM, Bleiweiss IJ (2001) Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol 32(6):583–589CrossRefPubMed

Barkley CR, Ligibel JA, Wong JS, Lipsitz S, Smith BL, Golshan M (2008) Mucinous breast carcinoma: a large contemporary series. Am J Surg 196(4):549–551CrossRefPubMed

Di Saverio S, Gutierrez J, Avisar E (2008) A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 111(3):541–547CrossRefPubMed

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM (1999) Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 17(5):1442–1448PubMed

Louwman MW, Vriezen M, van Beek MW, Nolthenius-Puylaert MC, van der Sangen MJ, Roumen RM, Kiemeney LA, Coebergh JW (2007) Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 121(1):127–135CrossRefPubMed

Luna-More S, Casquero S, Perez-Mellado A, Rius F, Weill B, Gornemann I (2000) Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol Res Pract 196(1):35–39CrossRefPubMed

Ng WK (2002) Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period. Cancer 96(5):280–288CrossRefPubMed

10.

Akiyoshi T, Nagaie T, Tokunaga M, Tajima M, Morita M, Nakatsuka A, Taga S, Wakiyama S, Ikebe M, Nakanishi K et al (2003) Invasive micropapillary carcinoma of the breast with minimal regional lymph node metastasis regardless of the huge size: report of a case. Breast Cancer 10(4):356–360CrossRefPubMed

11.

Madur B, Shet T, Chinoy R (2007) Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern. Acta Cytol 51(1):25–32CrossRefPubMed

12.

Shet T, Chinoy R (2008) Presence of a micropapillary pattern in mucinous carcinomas of the breast and its impact on the clinical behavior. Breast J 14(5):412–420CrossRefPubMed

13.

Bal A, Joshi K, Sharma SC, Das A, Verma A, Wig JD (2008) Prognostic significance of micropapillary pattern in pure mucinous carcinoma of the breast. Int J Surg Pathol 16(3):251–256CrossRefPubMed

14.

Ranade A, Batra R, Sandhu G, Chitale RA, Balderacchi J (2010) Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol 63(12):1043–1047CrossRefPubMed

15.

Barbashina V, Corben AD, Akram M, Vallejo C, Tan LK (2013) Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors. Hum Pathol 44(8):1577–1585CrossRefPubMed

16.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922PubMedCentralPubMed

17.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P et al (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 138(2):241–256CrossRefPubMedCentralPubMed

18.

Andre S, Cunha F, Bernardo M, Meneses J, Sousa E, Cortez F, Soares J (1995) Mucinous carcinoma of the breast: a pathologic study of 82 cases. J Surg Oncol 58(3):162–167CrossRefPubMed

19.

Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V (2004) Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol 17(9):1045–1050CrossRefPubMed

20.

Paramo JC, Wilson C, Velarde D, Giraldo J, Poppiti RJ, Mesko TW (2002) Pure mucinous carcinoma of the breast: is axillary staging necessary? Ann Surg Oncol 9(2):161–164CrossRefPubMed

21.

Rasmussen BB, Rose C, Christensen IB (1987) Prognostic factors in primary mucinous breast carcinoma. Am J Clin Pathol 87(2):155–160PubMed

22.

Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216(2):141–150CrossRefPubMed

23.

Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718–730CrossRefPubMed

24.

Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11(4):339–349CrossRefPubMed

Title: Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis
Authors: Fangfang Liu
Mu Yang
Zhenhua Li
Xiaojing Guo
Yang Lin
Ronggang Lang
Beibei Shen
Gordon Pringle
Xinmin Zhang
Li Fu
Publication date: 01-06-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3413-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Validation of self-reported post-treatment mammography surveillance among breast cancer survivors by electronic medical record extraction method

Retraction Note to: Suppression of the xCT–CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

Weight lifting and appendicular skeletal muscle mass among breast cancer survivors: a randomized controlled trial

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial

Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses’ health studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer